I wonder if $26K/year spent on exercise, occupational therapy, and good meals would be safer than this drug and superior to the placebo used in these trials.Also, "An F.D.A. official involved in the review of Leqembi said that “there were many important lessons learned” since the approval of Aduhelm." What were those lessons? Not violate the existing FDA protocols, e.g., not having secret meetings with Biogen, a company seeking drug approval? The NYTimes should do a little bit more digging into this Alzheimer's drug story.

I wonder if $26K/year spent on exercise, occupational therapy, and good meals would be safer than this drug and superior to the placebo used in these trials.Also, "An F.D.A. official involved in the review of Leqembi said that “there were many important lessons learned” since the approval of Aduhelm." What were those lessons? Not violate the existing FDA protocols, e.g., not having secret meetings with Biogen, a company seeking drug approval? The NYTimes should do a little bit more digging into this Alzheimer's drug story.

user
no
assistant